Scion Life Sciences
Andrew Marshall is currently a Venture Partner at Scion Life Sciences since September 2022. Previously, Andrew served as the Chief Editor at Nature Publishing Group, specifically leading Nature Biotechnology. Before that, Andrew was a Senior Editor at Current Biology and later became the Chief Editor of Current Opinion in Biotechnology. Andrew obtained their Doctor of Philosophy in Microbiology and Biotechnology from King's College London.
This person is not in any teams
Scion Life Sciences
Scion Life Sciences is a life sciences venture capital firm committed to meaningfully improving human health through long-term ownership of clinically transformative therapies. Our team of experienced innovators, company-builders and investors is founding and building exceptional biotechnology companies to discover, develop, and commercialize clinically transformational or curative new medicines. We aim to support impactful and sustainable advancements with a strategic and pragmatic approach to investment and innovation.